

The Winners of The 4th Kobayashi Foundation Award

Part 1 (Researchers)

NO	Title of Research	Applicant			
		Institution	First Name	Last Name	Country
1	A Novel Inhibitor of Nonhomologous End Joining Abrogates Double-Strand Break Repair and Impedes Cancer Progression	Indian Institute of Science	Sathees	RAGHAVAN	INDIA
Selection Reason					
Professor Raghavan discovered SCR7, a new molecular target drug. SCR7 has high novelty and is expected to be on the market as innovative drug for cancer chemotherapy in the future.					

Part 2 (Healthcare Professionals or Medical Teams)

NO	Subject for Medical Services	Applicant			
		Institution	First Name	Last Name	Country
1	1. Lung Cancer 2. Clinical Trials 3. Chemotherapy 4. Cancer Prevention	National Hospital and Cancer Research Center	Madan	PIYA	NEPAL
Selection Reason					
Dr. Piya has been widely contributing to spread cancer chemotherapy and enlighten people in Nepal for many years.					
2	Chemotherapy Treatment Review Clinic	National Cancer Centre Singapore (NCCS)	Vivianne	SHIH	SINGAPORE
Selection Reason					
The collaborative and proactive team has made effort to manage adverse events from cancer chemotherapy in outpatient setting and obtained excellent results.					